Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer

This study has been completed.
Information provided by (Responsible Party):
AHS Cancer Control Alberta Identifier:
First received: October 21, 2010
Last updated: October 1, 2014
Last verified: October 2014
Correlation between MRS and Tumor Response Therapy in Breast Cancer.

Condition Intervention
Breast Cancer
Device: MRS

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Correlation Between MRS (Magnetic Resonance Spectroscopy) and Tumor Response to Radiation Therapy in Breast Cancer

Resource links provided by NLM:

Further study details as provided by AHS Cancer Control Alberta:

Primary Outcome Measures:
  • MRS Correlation with Treatment Response [ Time Frame: Up to One Year ] [ Designated as safety issue: Yes ]
    measuring choline, water and fat levels by proton magnetic resonance spectroscopy in breast tumors in response to treatment

Secondary Outcome Measures:
  • Correlation with Tumor Stage [ Time Frame: Up to One year ] [ Designated as safety issue: Yes ]

Enrollment: 8
Study Start Date: December 2007
Study Completion Date: September 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: MRS
    Other Name: Philips 3 Tesla MRI Scanner
Detailed Description:
Correlation between MRS (Magnetic Resonance Spectroscopy and Tumor Response to Radiation in Breast Cancer

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed diagnosed Breast cancer
  • Patient is 18 years or older
  • Karnofsky performance score > 70
  • No previously irradiated or recurrent breast cancer
  • No contraindication to MRS/MRI
  • Signed informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01428739

Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Principal Investigator: Nadeem Pervez, MBBS, FFRRCSI, FRCPC Cross Cancer Institute
  More Information

Responsible Party: AHS Cancer Control Alberta Identifier: NCT01428739     History of Changes
Other Study ID Numbers: 23701 
Study First Received: October 21, 2010
Last Updated: October 1, 2014
Health Authority: Canada: Health Canada

Keywords provided by AHS Cancer Control Alberta:
Treatment response

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases processed this record on October 21, 2016